The Medical Travel Company Secures $4.5 Million Seed Funding to Expand UK–India Cross-Border Healthcare Platform

The Medical Travel Company, a UK and India‑based healthcare startup aiming to transform the fragmented medical tourism sector, has raised a $4.5 million seed funding round to scale its clinician‑led cross‑border care platform that connects UK patients with high‑quality, affordable treatment in India. The funding, announced in October 2025, marks a significant early milestone for the company founded by Ankit Mehrotra and Sahil Jain, serial entrepreneurs best known for building and exiting the restaurant discovery platform Dineout.

The seed round was led by Nexus Venture Partners, a prominent global venture capital firm with a focus on early‑stage technology companies, reflecting investor confidence in The Medical Travel Company’s full‑stack model for improving medical travel experiences. Alongside Nexus, investor participation came from Kriscore Capital, an early‑stage venture firm supporting disruptive startups, as well as an athlete‑led investment group, 4CAST, co‑founded by international cricket stars Ben Stokes, Jofra Archer, and KL Rahul, who invested through their collective.

The round also attracted a range of high‑profile angel investors who brought not only capital but also strategic support. Among these were Sriharsha Majety, co‑founder of Swiggy and a seasoned tech investor; Abhishek Goyal, founder of Tracxn; Dr. Ritesh Malik, founder of Innov8; Manish Vij of Smile Group; Arjun Vaidya of Dr. Vaidya’s and V3 Ventures; 1947 Rise Fund; and Peercheque, a startup investment platform.

Founded in 2024, The Medical Travel Company offers a “full‑stack” medical travel solution designed to address common pain points in the medical tourism industry, such as fragmented care, opaque pricing, and limited continuity after treatment. The company’s model ensures that UK clinicians oversee patient care from initial consultation through treatment in internationally accredited hospitals in India and back through a 12‑month post‑surgery insurance policy valid in the UK. Logistics, concierge services, and personalized aftercare form part of the comprehensive platform that aims to deliver a seamless healthcare journey for patients seeking elective procedures abroad.

According to founders Mehrotra and Jain, the platform initially prioritizes the UK–India corridor to address the challenges faced by millions of UK residents waiting for elective treatments like orthopaedics, dental, IVF, and other specialties, where long public system wait times and high private costs often drive patients to seek care overseas. The fresh capital from this raising will support expansion in both the UK and India, including strengthening clinical partnerships with accredited care providers and enhancing the company’s digital patient management infrastructure.

The startup’s vision extends beyond these two markets, with plans to enter additional regions such as the United States, Canada, Australia, and broader Europe over the next three to four years, reflecting a global ambition to make affordable, high‑quality clinical care accessible across borders. The funding will help lay the groundwork for this expansion by enabling technology development, bolstering customer acquisition efforts, and deepening relationships with healthcare systems and insurers.

Investor voices signaled strong support for The Medical Travel Company’s approach and potential. Pratik Poddar, Partner at Nexus Venture Partners, commented on the untapped potential of the medical tourism market and the startup’s capability to unlock value through its full‑stack model that blends clinical oversight with seamless operational support. Meanwhile, Kriscore Capital’s managing partner highlighted the founders’ track record of scaling consumer trust at Dineout as a key differentiator that positions the new venture for success in a complex sector. The involvement of cricket stars through 4CAST further underscores the broader appeal of the company’s mission and the confidence that high‑profile investors have in its future growth.

The funding round, which Dealroom lists at approximately €3.8 million, underscores the supportive investor landscape for healthcare innovation that addresses global scale challenges like medical wait times and affordability. As The Medical Travel Company builds its platform and extends its reach, the seed capital will be pivotal in establishing a trusted solution that reimagines cross‑border healthcare delivery and sets new standards for medical travel experiences.

With the fresh investment and growing recognition in the industry, The Medical Travel Company is poised to play an influential role in the growing medical tourism ecosystem, offering patients an alternative to traditional care pathways while creating opportunities for value creation and expanded access to quality healthcare worldwide.